TREATMENT OF BENIGN LYTIC BONE LESIONS WITH 45S5 BIOACTIVE GLASS: A CASE SERIES.

OBJECTIVE

To report a series of 9 cases of patients with benign cavitary tumor lesions who underwent intralesional resection (curettage) followed by cavity filling with 45S5 bioactive glass (Aktibone).

METHODS

This is a therapeutic case series study with level IV evidence. Patients diagnosed with benign lytic bone lesions who had a surgical indication for curettage followed by cavity filling with bioactive glass were included. In the postoperative period, patients underwent imaging examinations, which were qualitatively evaluated by a radiologist who determined the radiological diagnosis and the quality of osseointegration. The presence of imaging abnormalities was also assessed, and statistical analysis was performed.

RESULTS

Nine patients were included, 7 males and 2 females. The mean age was 25.8 years. The initial diagnoses varied, with enchondromas being the most frequent. The mean follow-up time after surgery was 8.4 months. All patients underwent preoperative radiographs. Most patients showed good clinical progression and good to partial osseointegration.

CONCLUSION

The results reinforce that 45S5 bioactive glass demonstrates good performance as a bone substitute in benign lytic lesions, providing adequate osseointegration and a low complication rate. Level of Evidence IV; Case series.